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Physical and biological range uncertainties limit the clinical potential
of Proton Beam Therapy (PBT). In these proceedings, we report on two
research projects, which we are conducting in parallel and which both
tackle the problem of range uncertainties. One aims at developing soft-
ware tools and the other at developing detector instrumentation. Regard-
ing the first, we report on our development and pre-clinical application of
a GPU-accelerated Monte Carlo (MC) simulation toolkit Fred. Concerning
the letter, we report on our investigations of plastic-scintillator-based PET
detectors for particle therapy delivery monitoring. We study the feasibility
of Jagiellonian-PET detector technology for proton beam therapy range
monitoring by means of MC simulations of the β+ activity induced in a
phantom-by-proton beams and present preliminary results of PET image
reconstruction. Using a GPU-accelerated Monte Carlo simulation toolkit
Fred and plastic-scintillator-based PET detectors, we aim at improving the
patient treatment quality with protons.
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1. Introduction
The increasing numbers of proton facilities and successful proton treat-
ments [1] indicate that the relevance of Proton Beam Therapy (PBT) as a
technique for tumor radiation therapy is rapidly growing. Kraków proton
facility has been in clinical operation since October 2016 and more than 10
patients a day are currently treated.
Range uncertainties, i.e. uncertainty of the distance that protons travel
inside patient body, currently represent one of the biggest caveats for the ex-
ploitation of the full potential of proton therapy treatments [2]. The proton-
beams range is particularly affected by biological and physical uncertain-
ties in a heterogeneous patient body. Therefore, to assure target coverage,
medical physicists currently apply up to about 1 cm safety margins around
the tumor volume, which lead to the unwanted irradiation of the healthy
tissues surrounding the tumor [2].
The biological dose, DRBE expressed in Gy(RBE), delivered to the pa-
tient is the actual quality of clinical interest. It is calculated as DRBE =
D × RBE, where D is the physical dose expressed in Gy and RBE is the
Relative Biological Effectiveness. By definition, in conventional therapy with
photons RBE = 1.0, therefore, physical and biological doses are equal and
correlated with clinical response. Protons have an increased biological ef-
fectiveness compared to photons, i.e. RBE is larger than one. Currently, in
clinical routine, the RBE of protons is assumed to be constant and equal
to 1.1 [3]. This convention neglects complex, often nonlinear dependency of
the RBE on such parameters as penetration depth, Linear Energy Transfer
(LET), dose, fractionation scheme, tissue type and endpoint, cell cycle phase
or oxygenation level. These dependencies might affect the effective proton
range, i.e., introduce biological range uncertainty and thus affect the dose to
the surrounding tissue and Organs at Risk (OAR). Modification of proton
physical dose by RBE, which is an uncertain weighting factor, makes the
correlation of proton biological dose and clinical effect of tumor irradiation
uncertain, and unification of clinical studies comparing the effectiveness of
different radiation modalities challenging.
An improvement resulting from the correctly applying radiobiological
assumptions in PBT could be achieved only under the condition that the
physical dose is accurately delivered to the patient. In fact, physical range
uncertainties, occurring due to patient mispositioning or Computed Tomog-
raphy (CT) scanner calibration introducing Hounsfield Unit (HU) to stop-
ping power conversion, could cause differences between treatment plan and
treatment delivery. Monte Carlo simulations and range monitoring meth-
ods are essential in PBT to guarantee that the physical dose is accurately
delivered and, therefore, to reduce the biological and physical range uncer-
tainties in a patient body.
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Figure 1 illustrates which role could play each of the two topics reported
in this manuscript in the clinical treatment workflow.
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Fig. 1. Diagram of the standard patient treatment protocol (light gray/blue colors)
along with activities of our group (dark gray/orange color) aiming to improve PBT
quality. We incorporate advanced nuclear physics computational and experimental
methods to predict physical and biological dose in patient more accurately and to
monitor proton beam range in patient by means of PET imaging.
2. Monte Carlo simulations to address physical and biological
range uncertainties of proton beams
It is recognized that Monte Carlo (MC) methods can offer improved
dose calculation accuracy in heterogeneous media and, therefore, predict
more accurately therapeutic dose distributions in patients compared to the
analytical algorithms that are typically employed in the Treatment Plan-
ning Systems (TPS) used in clinical routine [2]. Nowadays, the use of a
variable RBE is being discussed among the PBT scientific community. We
perform biological dose calculations with variable RBE and investigate bio-
logical range uncertainties by means of MC simulations of patient CT images
exploiting the MC dose calculation tool Fred [4, 5]. Fred offers a unique
combination of features: accuracy of an MC code including biological dose
computation, flexibility of a research tool, and high-dose calculation speed
due to GPU-acceleration. These characteristics are impossible to achieve
with the currently available commercial TPS and general purpose MC codes
such as Geant4/FLUKA [6, 7].
We have successfully implemented in Fred the proton beam model used
clinically for patient treatment in the Kraków facility. The Integrated Depth
Dose (IDD) profiles of single proton pencil beams in water simulated with
Fred MC code for different energies are in excellent agreement with the IDDs
obtained during the commissioning measurements (see Fig. 2, left), showing
differences of less than 2%.
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Fig. 2. Integrated depth dose distributions of proton pencil beams simulated in
Fred and obtained experimentally during the facility commissioning (left), an ex-
ample of transversal 2D dose distribution in isocentre plane obtained from FredMC
simulations (middle left), measured with MatriXX detector in water (middle right)
and a GI map computed from simulation and measurement using GI (3%/2mm)
method (right). GI passing rate is 98.64%.
The emittance model, describing lateral beam propagation in air, was im-
plemented in Fred, in accordance with the clinical system. The longitudinal
and lateral pencil beam shapes are modeled in FredMC with a submillimeter
precision.
We validated the beam model experimentally using the transversal pa-
tient treatment plan verification measurements. Such measurements are
routinely performed by medical physicists for treatment plan quality assur-
ance with an array of 1020 ionization chambers (MatriXX IBA) placed in a
water phantom. A transversal dose plane extracted from Fred MC and the
dose distribution measured with the MatriXX detector at the same depth
in water, as well as the Gamma Index (GI) map obtained from GI test are
presented in Fig. 2. The GI passing rate (3%/2mm criteria) greater than
98% was obtained for 182 dose planes measurements for 10 patients. Based
on these results, we can assure that dose distributions of clinical treatment
plans can be recalculated accurately.
We are currently performing treatment planning studies to quantify the
biological range uncertainties exploring various biological models with vari-
able RBE and clinical data of patients treated in Kraków.
An example of a selected Head and Neck (H&N) patient is presented
in Fig. 3, where the radiobiological dose distributions computed with con-
stant and variable RBE using Fred as well as corresponding Dose Volume
Histograms (DVHs) are shown. The MC calculation time for this case was
about 10min (9×108 primary protons, 2×106 p+s tracking rate). The mean
dose to Planning Target Volume (PTV), calculated with Fred using variable
RBE model proposed by Carabe [8], is increased with respect to the clini-
cally applied constant RBE = 1.1 assumption of about 3Gy(RBE), whereas
the maximum dose to the brain stem OAR increases by about 4Gy(RBE).
Our results show that incorporation of the variable RBE model in patient
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dose calculation increases the dose in PTV and OAR with respect to con-
stant RBE assumption. This is especially important when OARs are very
close to or overlap with the PTV as it occurs frequently in H&N patients.
Considering variable RBE hypothesis in the proton therapy clinic could be
essential as the increased biological dose deposited to OARs that exceeds
clinical dose constraints can be potentially associated with the increased
normal tissue complication probability and, therefore, an increased risk of
necrosis or secondary cancer.
Fig. 3. Left: the RBE-weighted dose with constant RBE= 1.1, middle-left: the
RBE-weighted dose with variable RBE (Carabe model [8]), middle-right: dose
difference between constant and variable RBE. DVH for constant and variable
RBE for PTV and brain stem.
The use of the fast MC dose computation tool Fred for physical and bi-
ological dose recalculation of patient treatment plans (retrospectively and
prospectively) can provide additional clinical information for medical physi-
cists and medical doctors, and can potentially prevent inaccuracies in patient
treatment.
3. J-PET detector to address physical range uncertainties
of proton beams
The proton interactions with patient tissues allow range monitoring dur-
ing or just after the treatment detecting emitted secondary radiation. Track-
ing of prompt-gamma, PET-gamma, and secondary protons and neutrons
are examples [9–11]. Prototype systems for prompt-gamma and PET-gamma
range monitoring were tested clinically and obtained satisfying precision of
Bragg peak position monitoring on-line in the PBT treatment room [12–14].
At the Jagiellonian University in Kraków, a novel solution for diagnostic
PET imaging, Jagiellonian-PET (J-PET) is being developed [15–18].
A single detection unit of the J-PET scanner [19] consists of a 50 cm long
and 6×24mm2 intersection size scintillator strip. The light pulses produced
in the strip by 511 keV back-to-back photons propagate to its edges, where
they are converted into electrical signals by photomultipliers (PMT). The
interaction position of the photon with the detector is estimated from the
time difference between the PMT signals located at the ends of the strip.
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A J-PET module consists of 13 scintillator strips read-out through a sin-
gle front-end electronics and an FPGA-based DAQ system. A modular,
lightweight and portable design of J-PET enables flexibility in detector con-
figuration and easy installation. Increasing the number of J-PET detector
layers, increases the detection efficiency of the system.
We performed comprehensive MC simulations using the GATE toolkit [20]
and reconstructions of 3D β+ activity distributions using the CASTOR soft-
ware [21]. The aim was to characterize the sensitivity of the J-PET for
proton beam range detection. We investigated single and multi-layer cylin-
drical and dual-head configurations of the J-PET modules that can be pos-
sibly applied for the in-room range monitoring. The list-mode TOF-MLEM
reconstruction (5 iterations with 500 ps TOF resolution without regulariza-
tion) takes into account random events, scatter, attenuation and normaliza-
tion corrections. Eventually, the reconstructed PET-activity profiles can be
correlated with the position of dose distal fall-off (Fig. 4, right) and used for
proton beam range monitoring.
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Fig. 4. The results of MC simulations. Top left: 2D distribution of dose deposited
by 150MeV proton beam in PMMA phantom; bottom left: β+ activity distribution
detected in J-PET and reconstructed with CASTOR software; right: dose, β+
production in PMMA, reconstructed signal from β+ activity detected with J-PET.
In this manuscript, we present preliminary results for one of the investi-
gated setup configurations, i.e. a single layer J-PET barrel (Fig. 5). Figure 4
illustrates a cross section through the centre of the beam of 3D dose distribu-
tion deposited in a 5×5×20 cm3 PMMA phantom by 108 protons of nominal
energy 150MeV (top left) and the same cross section of reconstructed 3D
distribution of β+ activity produced by the beam in the phantom (bot-
tom left). The activity map was reconstructed in the 5 × 5 × 5mm3 voxel
grid. The scintillator strips’ detection efficiency is taken into account in
MC simulations. The expected spatial and time resolutions of J-PET with
wavelength-shifting strips (WLS) [22] is taken into account through plastic
length discretization used in the simulations and image reconstruction.
Investigations on Physical and Biological Range Uncertainties . . . 15
Fig. 5. Single-layer modular J-PET barrel with isocentrically positioned PMMA
phantom.
Figure 4 (right) presents the MC simulated profiles of: (i) proton dose
deposition in the PMMA phantom, (ii) β+ activity produced in the phan-
tom, and (iii) actual signal detected by J-PET barrel from β+ activity. The
results show that the J-PET detector is feasible to acquire the β+ activity
produced during proton therapy treatment and that the offline 3D recon-
struction of PET activity images is possible using the CASTOR toolkit. The
characterization of J-PET sensitivity for proton beam range detection is
currently an ongoing research activity.
4. Summary
Within the research projects conducted in the Institute of Nuclear Physics
Polish Academy of Sciences in Kraków, we investigate physical and biological
range uncertainties of proton beams through positron emission tomography
(PET) based solutions and Monte Carlo (MC) simulations. Taking advan-
tage of the Fred accuracy and time performance possible due to the GPU
acceleration, we aim at improving quality assurance and treatment planing
in Kraków PBT facility. A Monte Carlo study of J-PET detector feasibility
performed in the frame of the project suggests that this technique might be
considered as a novel proton beam therapy range monitoring approach.
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